Explore our drug discovery
→

Computed tomography (CT)

Providing high-resolution anatomical imaging to support accurate localisation, co-registration, and translational decision-making.






























High-resolution anatomical imaging. Precise localisation.

Molecubes CT provides high-resolution anatomical imaging, enabling detailed visualisation of tissue structures and accurate localisation of radiotracer uptake when combined with functional imaging modalities. 

This is particularly important in the context of modern radiopharmaceutical development, where precise anatomical context, organ delineation, and accurate co-registration are essential for interpreting biodistribution, supporting dosimetry workflows, and improving confidence in translational decision-making. 

The integration of the Molecubes CT system enhances our translational imaging capability by providing critical anatomical reference, strengthening our ability to generate robust, co-registered datasets at the interface of discovery, radiopharmaceutical development, and clinical translation. 


Single-photon emission computed tomography (SPECT)






Access for all. Supporting partners working across oncology and emerging non-oncology indications.

The Molecubes CT system provides high-resolution anatomical small-animal imaging designed to support translational research and radiopharmaceutical development.

Built to deliver excellent spatial resolution and soft tissue contrast, the platform enables precise visualisation of anatomical structures in mouse and rat models, supporting accurate localisation of disease sites and biological processes. 

When integrated with functional imaging modalities such as PET and SPECT, the Molecubes CT system enables robust co-registration, 3D organ segmentation, and improved interpretation of biodistribution and target engagement.

This combined approach supports quantitative analysis, dosimetry workflows, and the generation of high-quality, clinically relevant datasets to inform translational decision-making and clinical progression. 


























Data we can provide with CT technology:

  • High-resolution whole-body anatomical imaging in mice and rats, enabling clear visualisation of organ structures and tumour localisation.
  • Detailed 3D anatomical datasets to support accurate organ delineation and structural assessment.
  • High-precision organ volume measurements to inform quantitative analysis and support dosimetry workflows.
  • Longitudinal CT imaging datasets enabling repeat imaging in the same animal for disease progression and therapy response monitoring.
  • Accurate tumour localisation and morphological assessment to complement functional imaging modalities.
  • Support for tumour-to-organ segmentation and volumetric analysis to enhance interpretation of therapeutic response.
  • 3D organ segmentation and co-registered CT datasets to provide anatomical context for PET and SPECT imaging and enable robust multi-modal analysis.
  • Structural inputs to support dosimetry modelling and preclinical-to-clinical translation workflows.
  • High-quality datasets enabling comparative cohort analysis and statistically robust evaluation of treatment or model-specific effects.



Benefits of computed tomography (CT)












  • High spatial resolution anatomical imaging – Enables precise visualisation of small anatomical structures, improving localisation and confidence in tumour and organ-specific analysis.
  • Accurate anatomical delineation – Supports reliable organ and tumour segmentation for volumetric analysis and structural assessment.
  • Essential anatomical context – Provides critical structural reference for interpreting functional imaging data from PET and SPECT.
  • Longitudinal study capability – Allows repeated imaging in the same animal, reducing variability and enabling monitoring of disease progression and therapy response.
  • Enhanced localisation and targeting – Improves accuracy of tumour identification and supports more confident assessment of therapeutic effects.
  • Integrated multi-modal co-registration – Combines seamlessly with PET and SPECT to enable precise alignment of functional and anatomical data for robust analysis and dosimetry workflows.
  • Supports quantitative imaging workflows – Enables organ volume measurements and structural inputs required for dosimetry modelling and translational studies.
  • Optimised for small-animal research – Delivers high-resolution imaging suited to mouse and rat models, supporting early-stage discovery and translational research.
  • Supports regulatory-aligned translational studies – Generates high-quality anatomical datasets that underpin IND-enabling imaging, dosimetry, and preclinical-to-clinical translation.






“The addition of Molecubes CT completes our end-to-end imaging platform, strengthening our ability to integrate high-resolution anatomical and functional imaging, and reinforcing our position at the forefront of radiopharmaceutical translation. It enhances the value we deliver to industry, academia, and funding partners. 

Make your next move count with our advanced anatomical insight from the Molecubes CT system.”

Dr Juliana Maynard, Head of Translational Imaging













See how we have helped innovators


Partnering with the MDC has been transformative for Innate Repair. Their world-class expertise and facilities allowed us to conduct complex oncology experiments quickly, cost-effectively, and to the highest scientific standards. MDC is an exceptional partner for any biotech aiming to accelerate innovation.

Innate Repair

Medicines Discovery Catapult R&D consulting provided Apeikon Therapeutics with clear direction and structured guidance, helping us define a robust product development plan. Their expertise streamlined our vision into actionable steps, accelerating progress and ensuring strategic alignment.

Apeikon Therapeutics

CPSA is an ingenious extension of the target engagement toolbox. It is easier to upscale and control in high throughput screening applications than currently available methods. With exemplary support from MDC we have smoothly incorporated it into our Drug Discovery pipeline.

Selvita

MDC’s R&D consulting has been transformative, refining our HT8457S strategy with scientific rigour, identifying and mitigating risks, and strengthening our business model, significantly enhancing Haiku’s credibility.

Haiku Therapeutics

The partnership with MDC has allowed us to secure multiple Innovate UK grants and utilise capabilities such as state-of-the-art PET, which aren’t available elsewhere.

Alchemab Therapeutics

For the first time, we have been able to generate a map of lung fibrosis in 3D at the tissue scale. Collaborating with MDC has been key to its success. Their expertise has supported the successful integration of state-of-the-art technologies, establishing a valuable new resource for the lung fibrosis community.

University of Southampton

Working with MDC allowed us to visualise drug distribution in the brain with a level of clarity we hadn’t achieved before. Their expertise in DESI-MS and willingness to design a project that met our demands provided powerful insights into diffusion patterns, giving us confidence in our compound’s delivery.

TargTex

We worked with the Mass Spectrometry team at MDC to help set up and run a complex biochemical assay. The project was technically demanding, but the deep expertise, knowledge and collaborative approach allowed the team to troubleshoot the many challenges and successfully deliver a viable approach.

Oppilotech

The team at MDC shares our passion for bringing forward innovative medicines, pioneering new technologies, and operating with data-driven flexibility. They have been integral to our project success and possess unique capabilities to support later-stage candidate selection. A truly valued collaborator and dependable partner.

Artbio

Elasmogen was impressed by the quality and rapid delivery timelines for our radiopharmaceutical dosimetry data. There was good interactivity in this project, and we are happy to recommend this service.

Elasmogen

Our collaboration with Medicines Discovery Catapult will not only enable us to engage with the wider scientific community but will also allow us to unlock the potential of Acoustic Mass Spectrometry within drug discovery.

Innovative Medicines and Early Development (IMED) Biotech Unit, AstraZeneca

It’s been absolutely amazing working with MDC and the team.

LUNAC Therapeutics

MDC supported us in developing a therapeutic for Huntington’s Disease through antibody characterisation, iPSC model development, biodistribution studies, imaging and neurodegenerative expertise.

Alchemab Therapeutics

We worked together with MDC on a very challenging and demanding project. The MDC team’s expertise in MSI, commitment and flexibility were key to a successful collaboration and reaching our objectives.

TargTex

MDC are as involved in our project as the founding team, going above and beyond what I expected. I recommend them to new ventures starting out; even if you don’t know exactly what you need, the team can work with you to achieve some phenomenal results.

KLAS Therapeutics

Working with MDC has provided expertise and intellectual input. It has also enabled access to a wider network of companies providing specialist services.

N4 Pharma

By tapping into MDC’s unique drug development expertise and facilities, we are confident we will accelerate the preclinical development of our drug delivery system and its commercialisation.

Sixfold Bioscience

It has been a pleasure working with MDC as their scientists are pleasant and have a broad range of talents.
Importantly for projects like ours, they openly and professionally exchange ideas with SMi’s scientific team and keep us abreast of their research developments.

SMi Systems

It has been great to access the Artificial Intelligence expertise at Medicines Discovery Catapult.
The team has taken an innovative approach that adds value to our product and will benefit our customers.

BioAscent

As an SME, working with MDC allows us access to scientific know-how and in vivo imaging techniques that would be impossible through any other route. The closeness, timeliness and flexibility of the collaboration significantly accelerated our ability to develop the product.

Xerion Healthcare

We have collaborated with MDC for three years, and it continues to provide valuable and high-quality data on our molecules. MDC’s input has directly impacted operational and strategic decisions for our projects and allowed us to move forward with our clinical studies.

Revolo Biotherapeutics

For early-stage SMEs in this space, I thoroughly recommend engaging with MDC, who have the end-to-end knowledge in complex medicines, can support your in-house team and provide access to key equipment that start-ups may not have.

pHion Therapeutics








Enhance your drug discovery project with computed tomography (CT) technology.

Fill in the form today and speak to us to see how we can help advance your drug discovery project.







Explore more

A photograph of a mass spectrometry laboratory with scientists working between machines
Mass Spectrometry

Find out more
Translational medicine

Find out more
Microscopy

Find out more



We are ISO 45001 certified 

The world’s first international standard for occupational health and safety. The accreditation has been certified by Interface NRM, a UKAS and ASI–accredited certification body.











Medicines Discovery Catapult